VRX, Valeant update

At around $170 this looked like a sell to us. It got to $308 so obviously we were off by about 1/2. Today we again think this is a sell. There are, arguable, 5 waves into the top and now the 5th wave is actually larger than wave one and three combined which is very unusual. The stock has traded up almost vertically and even left a gap behind between $220 to $240. For comparison purposes we include the US pharma+ ETF IBB which itself is a stellar performer but no match for VRX. This is one of those situation where things are “too good to be true”, perhaps because this is the only stock in this sector in Canada, there are no alternatives, except, of course, not playing at all.